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Immunoregulation and TGF-131. Suppression of a nephritogenic mu-
tine T cell clone. Transforming growth factor beta (TGF-13) has been
clearly linked in several model systems to the development of pathologic
extracellular matrix deposition in the glomerulus and interstitium. TGF-/3
additionally exerts multiple immunomodulatory effects on T and B
lymphocytes, including growth inhibition. Such pleiotropic effects make it
difficult to predict how TGF-j3 might directionally affect the expression of
T cell mediated kidney disease. We have examined the effects of TGF-/31
on the activity of effector T cells in a model of autoimmune interstitial
nephritis. M52.26 is an antigen-specific, nephritogenic, cytotoxic T cell
clone. TGF-/31 mediates a concentration-dependent inhibition of M52.26-
directed cytotoxicity of tubular epithelial cells in culture, and also of
M52.26-mediated transfer of interstitial nephritis to syngeneic recipients.
The loss of these functional activities is associated with distinct changes in
cytokine gene expression in M52.26. These cytokine alterations consist of
a loss of IFN-y and perform expression, and an up-regulation of TGF-/3
expression, which is likely relevant to the observed effector T cell
inactivation.
Suppression of undesirable immune responses remains an
investigative challenge in both understanding the pathogenesis
and treatment of autoimmune disease. Studies in a number of
experimental models have attempted to selectively down-regulate
injurious immune responses and alter susceptibility to disease by
targeting various components of T cell responses, such as cytokine
receptors or relevant accessory molecules required for T cell
activation [1, 2]. Recent studies of cytokines, such as TGF-/3,
which exert suppressive activity on different aspects of immune
responses, have explored the role of these endogenous peptides in
immune regulation [3, 4]. TGF-p, a 25 kD homodimeric peptide
with multiple isoforms, is a prototype of a large family of
ubiquitous peptide factors which are important in growth control,
development, and differentiation [5]. Activated TGF-/31, the most
abundant and best studied isoform, has multiple potent immuno-
modulatory effects on T cells in vitro, such as inhibiting growth,
differentiation, and effector function, and also altering T cell
cytokine release [3, 4]. Recent studies in immune-mediated renal
disease, however, have focused on the pathologic role played by
TGF-p1 in the development of glomerular sclerosis [6, 7] as a
marker of irreversible renal damage. In light of these diverse
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effects of TGF-/35, we thought it important to investigate TGF-
p1-mediated effects on antigen-specific T cells in the context of a
kidney-specific autoimmune disease.
As a model system for these studies, we have used a-tubular
basement membrane (aTBM) associated interstitial nephritis in
mice. aTBM disease is induced in susceptible rodents by immu-
nization with heterologous renal tubular antigen, or by the
adoptive transfer of renal antigen-specific effector T cells [8, 9].
We have recently characterized an effector T cell line, called M52,
which adoptively transfers interstitial nephritis to naive syngeneic
recipients, and also mediates both cytotoxic and DTH responses
to the target antigen 3M-i [8]. Clones established from this line
are functionally distinct, express distinct cytokine patterns and
elicit different patterns of interstitial injury following adoptive
transfer. One of these clones, M52.26, is cytotoxic to tubular
epithelial cells, does not mediate DTH, and elicits a lesion
comprised predominantly of tubular dilatation and atrophy, with-
out the marked inflammatory mononuclear infiltrates typically
observed in aTBM disease [10, manuscript submitted]. In previ-
ous studies we found that induced expression of TGF-/31 in
M52.26 cells was required for clonal inactivation by a clone
specific suppressor protein [manuscript submitted]. In the present
study, we examine the effect of exogenous TGF-j31 on M52.26-
mediated cytotoxicity of tubular epithelial cells, cytokine expres-
sion, and the ability of M52.26 to produce renal disease in vivo.
Our studies demonstrate that TGF-p1, as a single exogenous
factor, can inhibit the ability of M52.26 cells to initiate interstitial
nephritis.
Methods
Mice
SJL mice (H2s) were purchased from the Jackson Laboratory
(Bar Harbor, Maine, USA).
Cell preparations
The CTL clone, M52.26, was isolated from an immunized
mouse and propagated by weekly passage, as previously described
[8], with 20 Wml antigen (P1, a synthetic peptide fragment
derived from the cDNA sequence of the target antigen 3M-i
[11]), 20% MLA-144 supernatants as a source of IL-2, and 5 X 106
irradiated (2500 rads) syngeneic spleen cells. In experiments
evaluating the effect of exogenous TGF-p1 on T cell functions,
TGF-31 (purified from human platelets, R&D Systems, Inc.,
Minneapolis, Minnesota, USA) was added on day 1 of passage to
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Table 1. Oligonucleotide sequences of 5' and 3' primers
mRNA
species
5' Primer
(5' - 3')
3' Primer
(5' - 3')
Size of
product
bp
IL-2 [43] CCAC11TCAAGcTCTACAGCGG CcTFATGTGT[TGTAAGCAGGAGG 463
IL-4 [44] CCCAGGCCCGACAGCGAGACCC GCTI1TCTCTAACAGTAGGAAACC 302
IL-6 [45] CTACCAAACTGGATATAATC CCGAGTAGATCFCAAAGTGAC 330
IFN-y [14] CCCAATAAGAATAATfCTGCCAG GCTACAATCTGAGTTCAGTCAGC 308
TNF-a [46] CCGATGGGTFGTACCTTGTC AATGACTCCAAAGTAGACC 307
TGF-j3 [15] AAGAACFGCTGTGTGCGG GCATFGCAGGAGCGCACAA 299
Perform [16] GCATOCTFACCACAGGCTCATC GATAGCCTGTCTCAGAGCCfC 465
the final concentrations designated in each experiment. The
media was not changed in these cultures until the cells were
harvested for cytotoxicity assays, adoptive transfer, or RNA
preparation at day 5 following passage. When T cells were
counted for use in such studies, only viable cells were used. MCT
(SJL proximal tubular epithelial) cells were grown in DMEM
(JRH Biosciences, Lenexa, Kansas, USA) with 10% FCS [12].
They were used at confluence as target cells for cytotoxicity assays.
Adoptive transfer of disease
This technique of adoptive transfer has been extensively utilized
and previously described [8, 9, 11]. In brief, naive SJL mice were
anesthetized, and 25 x 106 viable lymphocytes (day 5 following
passage) in approximately 75 jil of PBS were injected under the
kidney capsule with a 30-gauge needle. Seven days later the
kidneys were harvested and examined histologically for the pres-
ence of interstitial injury.
Assessment of renal disease
The H & E stained kidney sections were coded for blind reading
by two different grading scales, as previously described [8]: 0 = no
involvement from the subcapsular cell layer; 0.5 = trace patho-
logic changes of cellular involvement in a focal pattern in the
outermost cortical tubular area; 1 = superficial, focal peritubular
infiltration and tubular atrophy under the transferred cell layer; 2
focal, deeply extending, heavy cellular infiltrates with peritubu-
lar damage and tubular atrophy. The sections were also graded by
approximating the tubular layer cell depth of interstitial injury.
Each layer equalled a tubular diameter and was given one point.
The data from both methods were expressed as a mean for each
group 5EM.
Cytotoxicity assays
This method determines target cell viability, and has been
described in detail previously [8]. In brief, the MCT target cells,
were prepared from confluent cultures, resuspended in medium
containing 0.5 Wml mitomycin C (Sigma Chemical Co., St. Louis,
Missouri, USA), dispensed into 96-well plates and allowed to
attach by overnight incubation at 37°C. Effector T cells were
harvested from day 5 cultures and separated by Lympholyte
(Cedarlane Laboratories, Ltd., Hornby, Ontario, Canada) extrac-
tion. Aliquots were then added to the adherent target cells at Elf
ratios of 5/1 to 50/1 in triplicate. Plates were incubated for 16 to
20 hours at 37°C. T cells were then washed from the wells, and the
wells replated with 180 1.d of fresh medium and 20 p.1 of Mfl' dye
(Sigma) solution (5 mg/mi in PBS). After four hours of incubation
at 37°C, medium and unreacted dye were aspirated from the wells
and 180 p.1 of 0.04 N HCI in isopropanol and 20 p.1 3% SDS were
added to solubilize the formazan dye. The OD at 570 nm of each
well was then determined using a spectrophotometer (Beckman
Instruments, Inc., Fullerton, California, USA). The mean and
standard deviation were determined for triplicate samples. The %
cytotoxicity was calculated by the following equation: % cytotox-
icily (1 — OD treated/OD control) X 100.
RNA extraction
Total cellular RNA was isolated from cultured T cells by the
single-step method of acid guanidium thiocyanate-phenol-chloro-
form extraction [131, and then used for Northern blot analyses and
reverse transcribed into cDNA for the polymerase chain reaction.
Northern blot hybridization
Total RNA isolated from 6 x 106 T cells was fractionated in a
1.5% agarose-formaldehyde gel and then transferred to a nylon
membrane, Blots were hybridized to 32P-labeled murine probes
for 16 hours at 55°C. Probes for IFN-y [14], TGF-/3 [15], perform
[16], and j3-actin [17] were used in these studies. After hybridiza-
tion the blots were washed three times with 0.1 X SSC/0.1% SDS
at 65°C for 30 minutes. Autoradiography was performed with
intensifying screens at —70°C.
PCR amplification of T cell transcripts
Reverse transcription of 10 p.g of T cell RNA was performed
with 0.25 mi's dNTPs (Boehringer Mannheim), 40 U of recombi-
nant RNasin (Promega Biotec, Madison, Wisconsin, USA), 0.01 M
dithiothreitol (Bethesda Research Laboratories, Gaithersburg,
Maryland, USA), 0.3 p.g oligo(dT)15, lx H-RT buffer (Bethesda
Research Laboratories), and 500 U of M-MLV reverse tran-
scriptase (Bethesda Research Laboratories). The reaction mixture
was incubated at 37°C for 60 minutes, heated at 95°C for 5 to 10
minutes, and then chilled on ice. PCR was performed with lx
PCR buffer II (Perkin-Elmer Cetus, Norwalk, Connecticut, USA),
final concentration 50 mi KC1, 10 mi's Tris-HC1, and 1.0 mM
MgC12 solution (Perkin-Elmer Cetus), 0.20 m dNTP (Boehr-
inger Mannheim), 0.40 pmoles each 3' and 5' primer, and 1.25 U
of Taq polymerase (Perkin-Elmer Cetus) in a total volume of 100
p.l. The sample was amplified with a Perkin-Elmer Cetus thermal
cycler. The amplification profile involved 35 cycles of denatur-
ation at 92°C for one minute, primer annealing at 50°C for one
minute, and extension at 72°C for two minutes. Ten microliters of
each PCR reaction mixture was electrophoresed in a 2% agarose
gel. Gels were stained with ethidium bromide and photographed.
Fig. 1. TGF-J31 inhibits M52.26-mediated cytotoxicily. Adherent target
cells (MCT) were incubated with M52.26 cells for 16 hours at 37°C and the
% cytotoxicity was determined from the amount of MTI' formazan
produced, as described in Methods. Concentrations of exogenous TGF-f31
to which the cells were exposed during their 5 day culture are: (El) control;(•)0.01 ng/ml TGF-f31; (D) 0.1 ng/ml TGF-/31; (4 1 ng/ml TGF-/31; ()
5 ng/ml TGF-p1. Each data point represents the mean of quadruplicate
samples. * P < 0.05 and # P < 0.025, Statistical significance of the curve
from control M52.26 cells based on two-way analysis of variance.
Oligonucleotides used for amplification
Oligonucleotides were synthesized on a DNA synthesizer (Ap-
plied Biosystems Inc., Culver City, California, USA). The sense
(5' primer) and antisense (3' primer) sequences used for these
PCR reactions and the source of the published murine cytokine
sequences are listed in Table 1.
Statistical analysis
Differences between experimental groups were determined by
Student's t-test, where appropriate. Cytotoxicity curves were
evaluated using two-way analysis of variance [18].
Results
We began our analysis by evaluating the ability of TGF-f31 to
inhibit effector T cell-mediated cytotoxicity of tubular epithelial
cells. Previous studies have demonstrated that M52 mediates
antigen-specific cytotoxicity toward 3M-i (target antigen) express-
ing syngeneic tubular epithelial cells (MCT) in a dose-dependent
manner [81. Both the M52 cell line and M52.26 (a CTL clone) are
cytotoxic to MCT between E/T ratios of 5/i and 50/1, where
cytotoxicity approaches 80% [8]. In order to test the effects of
TGF-31 on this interaction, M52.26 cells were exposed to TGF-/31
(0.01 to 5.0 ng/ml) on day 1 of culture and then tested for
cytotoxicity to MCT cells on day 5. As shown in Figure 1,
co-culture of M52.26 cells with TGF-/31 results in a concentration
dependent decrease in cytotoxicity. TGF-j31 at 0.01 ng/ml had no
effect on M52.26 mediated cytotoxicity (Fig. 1), whereas TGF-f31
at 1 or 5 ng/ml markedly inhibited M52.26 mediated cytotoxicity.
TGF-31 at 0.1 ng/ml resulted in a cytotoxicity curve between these
As recent studies have demonstrated that murine T cell clones
express distinct cytokine profiles which correlate with function
[19], we next determined whether the TGF-1-induced change in
M52.26 effector function was also associated with a change in
cytokine gene expression. Initial studies of M52.26 have revealed
a cytokine profile following activation with APC's and Ag char-
acterized by IL-4, IL-6, IFN-y, and TNF-a expression, but not
IL-2 or TGF-/3 expression [20]. M52.26 also expresses abundant
levels of perform, a potent mediator of cytotoxicity [20]. Figure 3
compares the expression of cytokine transcripts, detected by PCR,
of both M52.26 cells and cells pretreated with TGF-/31 (5.0 ng/ml).
The experimental groups of cells in these studies were harvested
for RNA extraction, reverse transcribed, and amplified by PCR
simultaneously. With this technique we observed reproducible
alterations in M52.26 cytokine expression. M52.26 cultured with
TGF-f31 (5.0 ng/ml) expressed marked decreases in IFN-y and
perform, as well as an increase in TGF-/3 expression. In order to
further investigate quantitative changes in cytokine gene expres-
sion, we performed Northern hybridization studies with RNA
derived from these experimental groups. The results of these
studies, shown in Figure 4, confirm the major cytokine changes
observed in M52.26. Following TGF-p1 treatment, TGF-f3 mes-
sage expression is induced (B), while IFN-y and perform expres-
sion (A,C) are no longer apparent. These alterations in mRNA
species following exposure to TGF-131 are reversible following
restimulation with irradiated antigen-presenting cells, IL-2, and
antigen in culture, at which point the clone regains its ability to
initiate interstitial nephritis (data not shown).
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two extremes which was significantly different than untreated cells
or those cocultured with 0.01 ng/ml TGF-p1.
We were therefore interested in evaluating the impact of
TGF-f31 on the nephritogenic potential of M52.26 in vivo. In these
studies, M52.26 cells were pretreated with varying concentrations
* of TGF-!31 in culture, and then transferred to naive syngeneic
mice. Seven days following T cell transfers the kidneys were
harvested and evaluated by light microscopy. Figure 2A demon-
strates the pattern of interstitial injury induced by M52.26. This
lesion is characterized by areas of microcystic change with tubular
dilatation and atrophy, and only mild mononuclear cell infiltra-
tion. A representative photo of the histology seen following
transfer of the cells pretreated with TGF-p1 (5.0 ng/ml) is found
in Figure 2B. In the latter group of kidneys we found no evidence
of interstitial disease, although we did observe a significant degree
of capsular reactivity to the cell transfers in the TGF-f31-treatedl•I•I.I.I 1 group. We frequently see such reactivity when transferred T cells0 10 20 30 40 50 60 fail to infiltrate the renal parenchyma.
Four groups of kidneys were formally evaluated by light micros-
copy to delineate both severity of injury and maximum depth of
the interstitial lesions. As seen in Table 2, TGF-f31 inhibited
M52.26-induced interstitial disease in a concentration-dependent
manner. Co-culture with 5.0 ng/ml completely prevented intersti-
tial disease, whereas 0.01 ng'ml had no effect on the nephritoge-
nicity of M52.26. Mild interstitial inflammation was observed at
0.1 ng/ml of TGF-p1, suggesting an incomplete inhibition of
transferred T cell clones at this concentration. Our adoptive
transfer and cytotoxicity studies were standardized to cell number,
in order to control for any antiproliferative effect of the exogenous
TGF-/31.
Effector: target ratio
B
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Fig. 2. TGF-j37 suppresses adoptive transfer of interstitial nephritis. Cultured M52.26 cells, untreated (A) or pulsed with TGF-131 (5.0 nglml) (B), were
injected under the kidney capsule of naive syngeneic mice. After 7 days the kidneys were harvested and sectioned for histologic grading. The interstitial
lesion typically seen after transfer of M52.26 cells is seen in (A). Focal areas of tubular atrophy and dilatation are apparent. M52.26 cells pretreated
with TGF-/31 do not infiltrate the renal parenchyma, as seen in (B). The interstitial architecture remains normal, and focal areas of capsular
inflammation are evident. (A,B 200x original magnification).
Table 2. TGF-31 inhibits adoptive transfer of interstitial nephritis
Histology after subcapsular
transfert
Cells injecteda Pretreatment Severity Maximum depth
M52.26 — 1.9 0.1 33.2 2.8
M52.26 TGF-j31 (5.0 ng/mI) 0 0
M52.26 TGF-/31 (1.0 ng/ml) 0.1 0.1c 1.7 1.6c
M52.26 TGF-131 (0.1 ng/ml) 0.4 0.30 7.8 4.10
M52.26 TGF-j31 (0.01 ng/ml) 1.5 0.2 27.0 7.1
a Cultured T cell clones were harvested from day 7 cultures. In some
groups, cells were pretreated with TGF-f31, on day 1 of culture. 25 x 106
cells in 75 gl of PBS were injected under the kidney capsule of naive SJL
mice. N = 3 to 6 for each group.
b Seven days after transfer, the kidneys were harvested and sectioned for
histologic grading as detailed in the Methods section
°P < 0.05 compared to M52.26 cells injected
Discussion
These studies demonstrate that TGF-j31 inhibits not only the
cytotoxicity of an antigen-specific CTL in vitro, but also its ability
to infiltrate the kidney and initiate interstitial nephritis following
adoptive transfer. M52.26 rendered unresponsive in this manner
exhibits reproducible alterations in cytokine gene expression. The
temporal association of these cytokine changes with the loss of
functional activity suggests that they are relevant to M52.26
inhibition. We have also observed that the TGF-j31-mediated
cytokine alterations in M52.26 cells are reversible, suggesting that
TGF-131 inhibition of nephritogenic T cells is not a result of an
irreverible toxic injury to effector T cells.
Previous studies have demonstrated that TGF-p1 can inhibit
the expression of autoimmune diseases in which T cells play an
important immunopathogenetic role. This immunosuppressive
effect has been demonstrated in several ways. Exogenous admin-
istration of TGF-131 suppresses EAE [21,22] and collagen arthritis
[23], neutralizing antibody to TGF-/31 causes enhancement of
disease expression [22,24], and tolerizing regimens (including oral
feeding of antigen) are associated with the induction of TGF-/31
expression [25]. TGF-/31 also appears to play a role in the the
spontaneous recovery from acute encephalomyelitis [26] and can
ameliorate disease even when administered after disease onset
[21]. These immunosuppressive effects of exogenous TGF-/31 on
autoimmune disease are consistent with the recent observation
that mice homozygous for a disrupted TGF-p1 gene develop
multifocal inflammatory disease leading to death at approximately
three weeks of age [27]. Renal involvement in these mice is
limited to serosal inflammation, but their short lifespan may
prevent the development of more widespread inflammatory renal
disease.
There are likely multiple mechanisms underlying this immuno-
suppressive effect of TGF-131. Recent studies have demonstrated
multiple, sometimes contradictory, immunoregulatory effects of
the TGF-f3 isoforms on various target cells and tissues [28]. In
vitro, these effects include inhibiting lymphocyte proliferation,
antagonizing inflammatory effector cytokines such as TNF-a and
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Fig. 3. Analysis of cytokine and perform
production of untreated and TGF-131-treated (5
rig/mi) M52.26 cells by RT/PCR of total RNA.
Amplified fragments of anticipated size were
detected by ethidium bromide staining of 2.0%
agarose gels.
Fig. 4. Northern hybridization studies of TGF-f31-induced changes in M52.26 cytokine expression. Ten g of total RNA derived from untreated and
TGF-/31-treated (5 ng/ml) M52.26 cells was electrophoresed, blotted onto a nylon membrane, and hybridized with (A) IFN-y, (B) TGF-p, and (C)
perform probes. The lower panels reveal the hybridization of the blots to a f3-actin probe and demonstrate the relative amount of RNA loaded in each
lane.
IFN-y, blocking CTL activity and DTH reactivity, and inhibiting
IL-i and IL-2 receptor induction [3, 4, 29—31]. The ability of
TGF-f31 to induce its own expression (Figs. 3 and 4)suggests that
in the context of our studies, autocrine production of TGF-/31 by
M52.26 cells following adoptive transfer may limit clonal expan-
sion in vivo. TGF-J3 also inhibits lymphocyte adhesion to endo-
thelial cells and downregulates class II expression on macro-
phages and astrocytes [32, 33]. In TGF-p1 null mice, both class I
and class II MHC mRNA levels are elevated, supporting a similar
directional effect of endogenous TGF-p1 on MHC expression
[34].
In addition to altering the expression of cytokine mediators and
cell surface recognition molecules, there is more recent informa-
tion that TGF-j31 can modulate the expression of collagenases by
macrophages [35, 36] and lymphocytes [37]. Bidirectional modu-
lation of the 92 kDa type IV collagenase in murine macrophages
by TGF-/31 occurs, with the direction of the effect dependent on
their activation by LPS: TGF-p1 inhibits the induction of the 92
kDa type IV collagenase by LPS, but in the absence of LPS
induces this activity [35]. Inhibition of type IV collagenase activity
by TGF-131 in activated nephritogenic lymphocytes might well
compromise their ability to infiltrate the renal interstitium, de-
grade basement membrane, and access tubular epithelial cells.
The cytokine alterations in TGF-f31 treated M52.26 cells are
intriguing to us for several reasons. The differential loss of IFN-y
expression suggests its importance in effector function, and has
also been reported in other models of autoimmunity. In EAE,
TGF-f3 reproduces the effects of previously described CD4 T
suppressor cells in inhibiting effector T cell IFN-y expression as
well as in suppressing disease in susceptible animals [38]. We have
observed that the loss of perform expression in M52.26 is associ-
ated with a reduced ability to kill renal tubular cells and to
infiltrate and damage renal parenchyma. Although some contro-
versy exists regarding the physiologic significance of perform-
expressing CTL, in situ perform expression has been detected in
areas of autoimmune injury [39, 40]. Previous studies have shown
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that TGF-f31 treatment of human peripheral blood CD8 T cells
results in a reversible concomitant loss of perform mRNA expres-
sion and lymphokine-activated killer activity [41]. Our observation
that down-regulation of perform expression in M52.26 is associ-
ated with marked inhibition of cytotoxicity and nephritogenicity is
consistent with perform being a relevant mediator for these
effector functions. Previous work has demonstrated the ability of
TGF-/31 to up-regulate its own mRNA [42]. In M52.26 cells, this
autocrine loop suggests that endogenously generated TGF-31
maintains clonal suppression in vivo following adoptive transfer.
TGF-/31 generated by the T cell in vivo may also act in a paracrine
fashion to diminish the immunologic visibility of tubular cells.
In immune-mediated renal disease, the beneficial immunosup-
pressive effects of TGF-f31 may be outweighed by its effects on the
accumulation of extracellular matrix. Studies in the acute mesang-
ial proliferative glomerulonephritis model have clearly demon-
strated that overproduction of TGF-p is critical for the pathologic
accumulation of extracellular matrix [6, 7]. Our studies demon-
strate that a nephritogenic T cell clone loses its ability to infiltrate
the kidney and attract other mononuclear cells following exposure
to TGF-f31. Since such infiltrating cells are frequently major
sources of TGF-131, it is quite possible that inhibiting the expan-
sion of the mononuclear cell infiltration will have a net beneficial
effect on kidney structure and function. Since M52.26 does not
express TGF-j31 following activation, it will be important to extend
our analysis and determine whether similar immunosuppressive
effects of TGF-131 are demonstrable on nephritogenic T cell clones
which do express TGF-p1 following activation or on the course of
spontaneous interstitial nephritis. Investigation of these issues is
underway in our laboratory.
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